Comparison of Efficacy and Safety of Deucravacitinib Versus Methotrexate in the Treatment of Moderate-to-Severe Plaque Psoriasis .
NCT07915492, Phase 4, Active not recruiting, Bangladesh Medical University
Trial 10
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
| Field | Value | Source |
|---|---|---|
| Title | Comparison of Efficacy and Safety of Deucravacitinib Versus Methotrexate in the Treatment of Moderate-to-Severe Plaque Psoriasis . | ClinicalTrials.gov |
| NCT number | NCT07915492 | ClinicalTrials.gov |
| Status | Active not recruiting | ClinicalTrials.gov |
| Phases | Phase 4 | ClinicalTrials.gov |
| Enrollment | 106 participants, estimated | ClinicalTrials.gov |
| Lead sponsor | Bangladesh Medical University | ClinicalTrials.gov |
| Conditions | Psoriasis | ClinicalTrials.gov |
| Interventions | Participants in group B will receive Methotrexate ,10mg tablets , once weekly for 28 weeks | ClinicalTrials.gov |
| First posted | 2026-11-04 | ClinicalTrials.gov |
| Last updated | 2026-11-04 | ClinicalTrials.gov |
Registered outcomes 4
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description | Source |
|---|---|---|---|---|
| Primary | Change in Psoriasis Area and Severity Index (PASI) | 30 days | Assessment of the change in Erythema, Induration, Desquamation scores as measured by the Psoriasis Area and Severity Index(PASI) from baseline to 30 days. The PASI is a composite scoring system ranging from 0 to 72 ,where higher score indicate greater disease severity and worse clinical outcome. | ClinicalTrials.gov |
| Primary | Change in Pruritus Visual Analog Scale (PVAS) | 30 days | Assessment of change in Pruritus Visual Analog Scale from baseline to 30 days. The PVAS measures itch severity. score range from 0 to 10 . Higher score indicate a worse outcome and greater symptom severity. | ClinicalTrials.gov |
| Primary | Adverse Effects | 30 days | Monitoring, recording and evaluating any adverse events observed during the 30-day study period, including elevated liver function tests ( LFTs), and infection and drug-related reactions. | ClinicalTrials.gov |
| Secondary | Dermatology Life Quality Index (DLQI) Score. | 30 days | Assessment of the change in Dermatology Life Quality Index (DLQI )Score from baseline to 30 days to evaluate the impact on patients quality of life. The QLQI is a 10-question questionnaire used to measure the impact of skin disease on patients quality of life .total score 0 to 30.Higher score indicate a worse quality of life . | ClinicalTrials.gov |
Outcomes 0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as | Source |
|---|
Results by group 0
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units | Source |
|---|
Participant flow 0
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted | Source |
|---|
Adverse events 0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events | Source |
|---|
Adverse event totals 0
The totals the trial posted for each group.
| Total | Group | Affected | At risk | Source |
|---|
Papers 0
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as | Source |
|---|
Grants 0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years | Source |
|---|
Trial comparisons 0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|
Tests 0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
| Test | Named as | Source |
|---|
Source 5
| Field | Value | Source |
|---|---|---|
| Release | trials-2026-11-12-0.4.0 | ClinicalTrials.gov |
| Release manifest SHA-256 | 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4 | ClinicalTrials.gov |
| Registry capture | 2026-11-12 | ClinicalTrials.gov |
| Results copy, AACT | 2026-03-23 | ClinicalTrials.gov |
| NIH clinical studies file | 2026-11-13 | ClinicalTrials.gov |
Release trials-2026-11-12-0.4.0
ClinicalTrials.gov's posted results, through CTTI's AACT: ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299 ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
ClinicalTrials.gov: none stated ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
NIH RePORTER's clinical studies and project files: Public domain (NIH RePORTER)